- Previous studies have found the human gut microbiome, bacteria in the gastrointestinal tract, is associated with cardiovascular disease (CVD).
- This study used machine learning to analyze data from nearly 1,000 stool samples from people with and without CVD.
- Results show potential for developing a convenient, new diagnostic approach for CVD.
Embargoed until 9 a.m. CT/10 a.m. ET Thursday, Sept. 10, 2020
DALLAS, Sept. 10, 2020 — Using artificial intelligence to analyze the bacteria in a person’s gut microbiome shows promise as a new screening method for cardiovascular disease (CVD), according to preliminary research to be presented Sept. 10-13, 2020, at the virtual American Heart Association’s Hypertension 2020 Scientific Sessions. The meeting is a premier global exchange for clinical and basic researchers focusing on recent advances in hypertension research. The full study published simultaneously today in Hypertension, an American Heart Association journal.
Recent studies have found a link between gut microbiota, the microorganisms in human digestive tracts, and CVD, which is the leading cause of mortality worldwide. Gut microbiota is highly variable between individuals, and differences in gut microbial compositions between people with and without CVD have been reported.
“Based on our previous research linking gut microbiota to CVD in animal models, we designed this study to test whether it is possible to screen for CVD in humans using artificial intelligence screening of stool samples,” said Bina Joe, Ph.D., FAHA, the study director, Distinguished University Professor and Chairwoman of the department of physiology and pharmacology at the University of Toledo in Toledo, Ohio. “Gut microbiota has a profound effect on cardiovascular function, and this could be a potential new strategy for evaluation of cardiovascular health.”
Researchers used data from the American Gut Project (an open platform for microbiome research based in the United States) to analyze microbial composition of stool samples with state-of-the-art machine learning modeling. Nearly 1,000 samples were analyzed, and approximately half of the samples were from people with CVD. The model was able to identify different clusters of gut bacteria that could potentially help identify individuals with existing CVD and without CVD.
Among the bacteria identified:
- Bacteroides, Subdoligranulum, Clostridium, Megasphaera, Eubacterium, Veillonella, Acidaminococcus and Listeria were more abundant in the CVD group.
- Faecalibacterium, Ruminococcus, Proteus, Lachnospira, Brevundimonas, Alistipes and Neisseria were more abundant in the non-CVD group.
“Despite the fact that gut microbiomes are highly variable among individuals, we were surprised by the promising level of accuracy obtained from these preliminary results, which indicate fecal microbiota composition could potentially serve as a convenient diagnostic screening method for CVD,” Joe said. “It is conceivable that one day, maybe without even assessing detailed cardiovascular function, clinicians could analyze the gut microbiome of patients’ stool samples with an artificial machine learning method to screen patients for heart and vascular diseases.”
Co-authors are Sachin Aryal, B.S.; Ahmad Alimadadi, Ph.D.; Ishan Manandhar, B.S.; and Xi Cheng, Ph.D. This study was funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health.
- Available multimedia is on right column of release link https://newsroom.heart.org/news/gut-microbiome-data-may-be-helpful-in-routine-screening-of-cardiovascular-disease?preview=6cf1f65c0a8182ce0a406a455e5d3ed7
- After Sept. 10, view the manuscript online.
- Gut Microbiota and Cardiovascular Disease
- Specific gut bacteria may be associated with pulmonary arterial hypertension
- Follow AHA/ASA news on Twitter @HeartNews #Hypertension20
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect Association policy or position. The Association makes no representation or warranty as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at https://www.heart.org/en/about-us/aha-financial-information.
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173
William Westmoreland: 214-706-1232, email@example.com
For Public Inquiries: 1-800-AHA-USA1 (242-8721)